Dissecting unique functions of IgM and IgD BCRs in tolerance and autoimmunity
剖析 IgM 和 IgD BCR 在耐受和自身免疫中的独特功能
基本信息
- 批准号:9193713
- 负责人:
- 金额:$ 34.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-06-01 至 2021-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAntibodiesAntigen PresentationAntigensAutoantibodiesAutoantigensAutoimmune DiseasesAutoimmune ResponsesAutoimmunityB cell repertoireB-Cell ActivationB-Cell DevelopmentB-LymphocytesBindingBiochemical GeneticsBiological MarkersBone MarrowCD22 geneCellsCharacteristicsCoupledCouplingDataDevelopmentDiseaseDown-RegulationEpitopesGerm LinesGoalsHealthHomeostasisHumanImmuneImmune ToleranceImmune responseImmunizationImmunoglobulin Class SwitchingImmunoglobulin DImmunoglobulin MLigationMediatingMembraneModelingMusMutateMutationNuclearNucleic Acid BindingNucleic AcidsPTPRC genePathogenesisPatientsPlayPopulationProcessProductionPropertyProtein Tyrosine PhosphataseReceptor SignalingReceptors, Antigen, B-CellRecruitment ActivityReporterRoleSignal PathwaySignal TransductionSpecificitySystemic Lupus ErythematosusT-LymphocyteTherapeutic InterventionTimeantigen bindingautoreactive B cellautoreactivitycentral tolerancegenetic approachin vivolupus prone micemouse modelnovelperipheral tolerancepreventreceptorresponsetrafficking
项目摘要
Project Summary: “Dissecting unique functions of IgM and IgD BCRs in tolerance and autoimmunity”
The prototypical autoimmune disease systemic lupus erythematosus (SLE) is characterized by anti-
nuclear autoantibodies (ANAs) that serve not only as critical biomarkers of disease, but also play a central role
in pathogenesis. Surprisingly, despite central tolerance mechanisms such as receptor editing and deletion of
autoreactive B cells during bone marrow development, up to 30% of mature human B cells nevertheless harbor
some degree of ANA-reactivity. This suggests that additional peripheral tolerance mechanisms must keep such
potentially dangerous clones in check. We have recently characterized a novel fluorescent reporter mouse line,
Nur77-eGFP, that is sensitive to antigen-dependent B cell receptor (BCR) signaling in vivo. The most highly
fluorescent naïve B cells from these mice have recognized endogenous antigen, and are enriched for ANA-
reactivity. The Nur77-eGFP reporter thus identifies ANA-reactive B cells in a diverse, normal repertoire,
enabling us to track and isolate such cells. We have shown that these ANA-reactive B cells down-regulate
expression of the IgM isotype BCR, resulting in dampened responses to IgM stimulation. However, naïve B
cells uniquely express a second BCR isotype, IgD, with the same epitope-binding domain as IgM. In contrast to
IgM, IgD expression and signaling in ANA-reactive B cells are unperturbed. How does IgM downregulation limit
autoimmune responses to self-antigens despite high IgD expression? Each BCR isotype alone is capable of
mediating B cell development and responses to immunization with model antigens. In contrast to such
apparent redundancy, we have new preliminary data to show that B cells lacking IgM and expressing only IgD
are completely prevented from contributing to autoantibody production in a mouse model of SLE. It has
recently been shown that IgM, but not IgD, is uniquely sensitive to monovalent antigens. However, relevant
nucleic acid-associated autoantigens in SLE are thought to be membrane associated and multivalent
suggesting that other distinctive properties of IgM may be important for autoantibody production. In this
proposal we intend to identify the mechanisms by which IgM and IgD differentially regulate B cells in the
context of health and disease. To do so: (1) We will take advantage of mice deficient for either IgM or IgD to
explore how B cells expressing each isotype alone are recruited to secrete pathogenic autoantibodies in two
models of systemic autoimmunity with distinct disease mechanisms (Lyn-/- and BAFF Tg). (2) We will
determine how the IgM and IgD BCRs traffic to endosomal compartments to recruit costimulatory signals via
TLRs7/9 and via MHCII presentation of antigen to T cells. (3) We will explore how differential coupling of IgM
and IgD to B cell stimulatory and inhibitory co-receptors alters downstream signaling and contributes to B cell
tolerance. Together these studies will define how IgM down-modulation limits B cell responses to self-
antigens. This tolerance checkpoint may represent a novel target for therapeutic intervention to re-
establish immune homeostasis in patients with SLE and other autoantibody-mediated diseases.
项目总结:“剖析免疫球蛋白M和免疫球蛋白受体在耐受和自身免疫中的独特功能”
典型的自身免疫性疾病系统性红斑狼疮(SLE)的特点是抗-
核自身抗体(Ana)不仅是疾病的关键生物标志物,而且还发挥着核心作用
在发病机制上。令人惊讶的是,尽管中枢耐受机制,如受体编辑和删除
自身反应性B细胞在骨髓发育过程中,高达30%的成熟人类B细胞仍含有
有一定程度的抗核抗体反应性。这表明,额外的外周耐受机制必须保持这种
有潜在危险的克隆人被控制住了。我们最近鉴定了一种新的荧光报告鼠系,
Nur77-EGFP,体内对抗原依赖的B细胞受体(BCR)信号敏感。最高级别的
来自这些小鼠的荧光幼稚B细胞识别内源性抗原,并对ANA-
反应性。因此,Nur77-EGFP报告者在不同的、正常的谱系中识别ANA反应的B细胞,
使我们能够追踪和分离这些细胞。我们已经证明,这些ANA反应性B细胞下调
IgM同型bcr的表达,导致对IgM刺激的反应减弱。然而,天真的B
细胞唯一地表达第二种BCR同种异型IGD,具有与IgM相同的表位结合域。与之形成鲜明对比的是
IgM、IGD在ANA反应性B细胞中的表达和信号转导不受干扰。IgM下调如何限制
尽管免疫球蛋白高表达,自身抗原的自身免疫反应?每个bcr亚型单独能够
调节B细胞发育和对模型抗原免疫的反应。与此形成对比的是
明显的冗余,我们有新的初步数据表明B细胞缺乏IgM,只表达IGD
完全被阻止在SLE小鼠模型中促进自身抗体的产生。它有
最近的研究表明,对单价抗原唯一敏感的是IgM,而不是IgD。然而,相关的
系统性红斑狼疮中的核酸相关自身抗原被认为是膜相关的多价抗原。
这表明,IgM的其他独特特性可能对自身抗体的产生也很重要。在这
我们打算确定IgM和IGD对B细胞的不同调节机制
健康和疾病的背景。为此:(1)我们将利用免疫球蛋白M或免疫球蛋白D缺陷的小鼠
探索单独表达每种同型的B细胞如何被招募来分泌致病自身抗体
具有不同疾病机制的系统性自身免疫模型(LYN-/-和BAFF-TG)。(2)我们会
确定IgM和IGD BCRs如何通过传输到内体隔室来招募共刺激信号
TLRs7/9,并通过MHCII将抗原提呈给T细胞。(3)我们将探索IgM的差示偶联
而IGD到B细胞的刺激性和抑制性共受体改变下游信号转导并促进B细胞
宽容。这些研究将共同定义IgM下调如何限制B细胞对自身的反应
抗原。这一耐受检查点可能代表着治疗干预的一个新靶点。
在系统性红斑狼疮和其他自身抗体介导的疾病患者中建立免疫稳态。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JULIE ZIKHERMAN其他文献
JULIE ZIKHERMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JULIE ZIKHERMAN', 18)}}的其他基金
Regulation of CD4 T cell tolerance by the NR4A family of nuclear receptors
核受体 NR4A 家族对 CD4 T 细胞耐受性的调节
- 批准号:
10707222 - 财政年份:2022
- 资助金额:
$ 34.87万 - 项目类别:
Regulation of CD4 T cell tolerance by the NR4A family of nuclear receptors
核受体 NR4A 家族对 CD4 T 细胞耐受性的调节
- 批准号:
10599024 - 财政年份:2022
- 资助金额:
$ 34.87万 - 项目类别:
Nuclear Receptors in B Cell Tolerance and Humoral Immune Responses
B 细胞耐受和体液免疫反应中的核受体
- 批准号:
10626756 - 财政年份:2020
- 资助金额:
$ 34.87万 - 项目类别:
Nuclear Receptors in B Cell Tolerance and Humoral Immune Responses
B 细胞耐受和体液免疫反应中的核受体
- 批准号:
10410354 - 财政年份:2020
- 资助金额:
$ 34.87万 - 项目类别:
Nuclear Receptors in B Cell Tolerance and Humoral Immune Responses
B 细胞耐受和体液免疫反应中的核受体
- 批准号:
10192648 - 财政年份:2020
- 资助金额:
$ 34.87万 - 项目类别:
Dissecting unique functions of IgM and IgD BCRs in tolerance and autoimmunity
剖析 IgM 和 IgD BCR 在耐受和自身免疫中的独特功能
- 批准号:
9899730 - 财政年份:2016
- 资助金额:
$ 34.87万 - 项目类别:
Dissecting unique functions of IgM and IgD BCRs in tolerance and autoimmunity
剖析 IgM 和 IgD BCR 在耐受和自身免疫中的独特功能
- 批准号:
9479603 - 财政年份:2016
- 资助金额:
$ 34.87万 - 项目类别:
Titrating CD45 expression in mice to study development of T cell tolerance
滴定小鼠 CD45 表达以研究 T 细胞耐受的发展
- 批准号:
8098871 - 财政年份:2010
- 资助金额:
$ 34.87万 - 项目类别:
Titrating CD45 expression in mice to study development of T cell tolerance
滴定小鼠 CD45 表达以研究 T 细胞耐受的发展
- 批准号:
8701864 - 财政年份:2010
- 资助金额:
$ 34.87万 - 项目类别:
Titrating CD45 expression in mice to study development of T cell tolerance
滴定小鼠 CD45 表达以研究 T 细胞耐受的发展
- 批准号:
7952505 - 财政年份:2010
- 资助金额:
$ 34.87万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 34.87万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 34.87万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 34.87万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 34.87万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 34.87万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 34.87万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 34.87万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 34.87万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 34.87万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 34.87万 - 项目类别:














{{item.name}}会员




